期刊文献+

五酯软胶囊和甲磺酸伊马替尼片联合给药后对大鼠体内伊马替尼药动学的影响 被引量:2

Effects of Wuzhi Soft Capsule Combined with Imatinib Mesylate Tablet on Pharmacokinetics of Imatinib in Rats after Administration
下载PDF
导出
摘要 目的:研究五酯软胶囊和甲磺酸伊马替尼片联合给药后对大鼠体内伊马替尼药动学的影响。方法:将大鼠分为单次给药组和连续给药组。单次给药组大鼠分为伊马替尼1组(灌胃空白大豆油+伊马替尼混悬液10 mg/kg),五酯软胶囊低、中、高剂量+伊马替尼组(灌胃五酯软胶囊溶液134、268、536 mg/kg+伊马替尼混悬液10 mg/kg),每组6只,各组大鼠灌胃空白大豆油/五酯软胶囊溶液30 min后再灌胃伊马替尼混悬液。连续给药组大鼠分为伊马替尼2组(灌胃空白大豆油+灌胃伊马替尼混悬液10 mg/kg),五酯软胶囊低剂量+伊马替尼组(灌胃五酯软胶囊溶液134 mg/kg+伊马替尼混悬液10 mg/kg),每组6只,各组大鼠连续灌胃空白大豆油/五酯软胶囊溶液14 d,每天1次,末次给药30 min后,再灌胃伊马替尼混悬液。各组大鼠分别于伊马替尼给药前和末次给药后0.5、1、2、2.5、3、4、5、6、8、12、24、36 h取血100μL,采用高效液相色谱-串联质谱(HPLC-MS/MS)法测定大鼠血浆中伊马替尼的血药浓度,绘制药-时曲线,并用DAS 2.0软件拟合药动学参数。结果:单次给药后,与伊马替尼1组比较,五酯软胶囊低、中、高剂量+伊马替尼组大鼠c_(max)、t_(1/2)、AUC_(0-36 h)、AUMC_(0-36 h)均显著增加(P<0.05或P<0.01);连续给药后,与伊马替尼2组比较,伊马替尼+五酯软胶囊低剂量组大鼠c_(max)、t_(1/2)、AUMC_(0-36 h)均显著增加(P<0.05或P<0.01)。结论:五酯软胶囊单次给药和连续给药均对伊马替尼的药动学有影响,可增加伊马替尼血药浓度,并延长其半衰期。 OBJECTIVE:To study the effects of Wuzhi soft capsule and imatinib mesylate tablet on the pharmacokinetics of imatinib in rats. METHODS:The rats were divided into single administration group and consecutive administration group. The single administration group was divided into imatinib group one(ig administration of blank soybean oil+imatinib suspension 10 mg/kg),low-dose,medium-dose and high-dose of Wuzhi soft capsule+imatinib group(ig administration of Wuzhi soft capsule solution 134,268,536 mg/kg + imatinib suspension 10 mg/kg),with 6 rats in each group. Each group was given imatinib suspension intragastrically 30 min after intragastric administration of blank soybean oil/Wuzhi soft capsule solution. The consecutive administration group was divided into imatinib group two(ig administration of blank soybean oil+imatinib suspension 10 mg/kg), Wuzhi soft capsule low-dose+imatinib group(ig administration of Wuzhi soft capsule solution 134 mg/kg+imatinib suspension 10 mg/kg),with 6 rats in each group. Each group was given blank soybean oil/Wuzhi soft capsule solution intragastrically for consecutive 14 d,once a day;30 min after last administration,ig imatinib suspension. About 100 μL blood was collected before imatinib,0.5,1,2,2.5,3,4,5,6,8,12,24 and 36 h after medication. The plasma concentration of imatinib was determined by HPLC-MS/MS. The pharmacokinetic parameters were fitted by using DAS 2.0 software. RESULTS:After single administration, compared with imatinib group one,cmax,t1/2,AUC0-36 h and AUMC0-36 h in low-dose,medium-dose and high-dose of Wuzhi soft capsule + imatinib group were increased significantly (P<0.05 or P<0.01). After consecutive administration,compared with imatinib group two,cmax,t1/2 and AUMC0-36 h of imatinib+low-dose of Wuzhi soft capsule group were increased significantly(P< 0.05 or P<0.01). CONCLUSIONS:Single administration and consecutive administration of Wuzhi soft capsule influence the pharmacokinetics of imatinib, increase plasma concentration of imatinib and prolong half-time.
作者 徐文 刘涛 赵振寰 曹志红 吕志强 马敏 马霖 XU Wen;LIU Tao;ZHAO Zhenhuan;CAO Zhihong;LYU Zhiqiang;MA Min;MA Lin(Dept. of Pharmacy,the Affiliated Hospital of Qingdao University,Shandong Qingdao 266003,China)
出处 《中国药房》 CAS 北大核心 2019年第9期1198-1202,共5页 China Pharmacy
基金 山东省自然科学基金资助项目(No.ZR2017MH045)
关键词 五酯软胶囊 伊马替尼 大鼠 药动学 高效液相色谱-串联质谱 Wuzhi soft capsule Imatinib Rat Pharmacokinetics HPLC-MS
  • 相关文献

参考文献2

二级参考文献22

  • 1杜春燕,师英强.胃肠道间质瘤诊治进展[J].中国实用外科杂志,2006,26(2):158-160. 被引量:35
  • 2Blanke CD, Demetri GD, von Mehren M, et al. Long-term resultsfrom a randomized phase II trial of standard- versus high-er—dose imatinib mesylate for patients with unresectable or met-astatic gastrointestinal stromal tumors expressing KIT[j]. J ClinOncol, 2008, 26(4):620-625. 被引量:1
  • 3Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levelsare correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors [J]. J Clin Oncol,2009, 27(19):3141-3147. 被引量:1
  • 4Judson I, Ma P, Peng B, et al. Imatinib pharmacokinetics in pa- tients with gastrointestinal stromal tumour: a retrospective popu- lation pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group[J]. Can Chem Phar, 2005, 55(4):379-386. 被引量:1
  • 5Casali PG, Blay JY. Gastrointestinal stromal tumours: ESMOClinical Practice Guidelines for diagnosis, treatment and foi-low-up[j]. Ann Oncol, 2010, 21 (suppl 5):98-102. 被引量:1
  • 6Demetri GD, von Mehren M, Antonesnu CR, et al. NCCN TaskForce report: update on the management of patients with gastro-intestinal stromal tumors[j]. J NCCN, 2010, 8 (suppl 2):1-44. 被引量:1
  • 7Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib[J]. Clin Pharma, 2005, 44(9):879-894. 被引量:1
  • 8Gambacorti-Passerini C, Zucchetti M, Russo D, et al. Alphalacid glycoprotein hinds to imatinib (STI571) and substantially al-ters its pharmacokinetics in chronic myeloid leukemia patients[J]. Clin Can Resea, 2003,9(2):625-632. 被引量:1
  • 9Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacoki-netics and its correlation with response and safety in chron-ic-phase chronic myeloid leukemia: a subanalysis of the IRISStudy [J], Blood, 2008, 111(8):4022-4028. 被引量:1
  • 10Davies A, Hayes AK, Knight K, et al. Simultaneous determina-tion of nilotinib, imatinib and its main metabolite (CGP-74588)in human plasma by ultra-violet high performance liquid chro-matography [j ].Leukemia Resea, 2010, 34(6):702-707. 被引量:1

共引文献8

同被引文献25

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部